Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 154 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for SAD Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Progerinin in Healthy Volunteers

NCT04512963
View directory record Official record
Conditions
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Interventions
Progerinin, Placebo
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

NCT03758612
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1, TBI-223 SR Tablet Prototype 2, TBI-223 SR Tablet Prototype 3, TBI-223 IR Tablet, Placebo suspension
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 2, 2026, 5:24 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients

NCT02778386
View directory record Official record
Conditions
Toxicity
Interventions
N-Methanocarbathymidine, Placebo Capsule
Drug · Other
Lead sponsor
N&N Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 2, 2026, 5:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Alcohol and Mood on Attention

NCT04276779
View directory record Official record
Conditions
Suicidal Ideas
Interventions
Alcohol administration, Placebo administration, Positive mood induction, Negative mood induction
Other · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

NCT06432647
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ATH-1105, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

NCT01590654
View directory record Official record
Conditions
Hepatitis B
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

NCT04909242
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DZD9008, Placebo
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

NCT02834741
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NYX-2925
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 2, 2026, 5:24 PM EDT
Terminated Phase 4 Interventional Results available

A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

NCT03078270
View directory record Official record
Conditions
Anxiety Disorder Social, Anxiety
Interventions
botulinum toxin A, Placebo
Drug · Other
Lead sponsor
Daniel Lieberman
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 2, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of BLKR201 in Healthy Adult Participants

NCT07501039
View directory record Official record
Conditions
Healthy
Interventions
BLKR201, Placebo
Drug
Lead sponsor
Formation Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
View directory record Official record
Conditions
Phenylketonuria, Healthy
Interventions
SYNB1618, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

NCT05163522
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

NCT06679959
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC30 Injection, for subcutaneous use or placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

NCT06226454
View directory record Official record
Conditions
Pain
Interventions
VX-993, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641
View directory record Official record
Conditions
Hepatitis B, HBV
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 2, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Single and Multiple Dose of HL-400

NCT06997484
View directory record Official record
Conditions
Parkinson Disease
Interventions
HL-400, Placebo
Drug
Lead sponsor
Highlightll Pharmaceutical (USA) LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 5:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of IGM-6268 in Healthy Volunteers

NCT05160402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IGM-6268, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-235 in Healthy Subjects

NCT05246878
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Results available

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

NCT02036645
View directory record Official record
Conditions
Mild-Moderate Alzheimer's Disease, Healthy Elderly
Interventions
MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Glendale, California • Long Beach, California • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 2, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818
View directory record Official record
Conditions
Graves Disease
Interventions
MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD
Biological
Lead sponsor
Merida Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Torrance, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 2, 2026, 5:24 PM EDT